Work

Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

Year: 2017

Type: article

Study design: Observational Study

Source: Clinical Gastroenterology and Hepatology

DOI: 10.1016/j.cgh.2017.03.031

Authors: Konstantinos Papamichael, Karen A. Chachu, Ravy K. Vajravelu, Byron P. Vaughn, Josephine Ni, Mark T. Osterman, Adam S. Cheifetz

Institutions: Beth Israel Deaconess Medical Center, Harvard University, Duke University, Duke Medical Center, University of Pennsylvania, University of Minnesota

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences

Awards: G1148219579, G135351990, University of Minnesota Clinical and Translational Science Institute (UMN CTSI), Training Program in Gastrointestinal Sciences

OpenAlex ID: W2599446307

FWCI: 19.13

Cites: 27

Cited by: 226

Related to: 10